Skip to Content

Nuvilex Announces Invitation to Showcase Innovative Therapy for Cancer Treatment at Oncology Meeting in Kyoto, Japan

SILVER SPRING, Md.--(BUSINESS WIRE)--Apr 18, 2012 - Nuvilex, Inc. (OTCQB:NVLX) reports that the Chairman of its associate company, SG Austria, Prof. Walter H. Gunzburg, has been invited to present data about the proprietary encapsulation of living cell technology, in particular for the treatment of pancreatic cancer and other solid tumors, at the 8th Annual Meeting of the Organisation for Oncology and Translational Research (OOTR).

The meeting, which focuses on Cancer Therapy, will be held in Kyoto, April 20 – 21, 2012. Professor Gunzburg's presentation is entitled “Encapsulation of Cells as an Innovative Therapy for the Treatment of Cancer and Other Severe Diseases” and will include clinical trial data from the pancreatic cancer patients treated with encapsulated cells with low dose chemotherapy.

This invitation represents another important milestone for Nuvilex and SG Austria as the companies move forward from the previously completed Phase 1 and 2 clinical trials towards eventual market acceptance.

Dr. Robert Ryan, Chief Executive Officer of Nuvilex, commented, “Dr. Gunzburg and I are extremely excited that SG Austria's expertise in this field is being recognized by the medical/clinical community. The living cell encapsulation technology forms the basis for a whole host of novel medical treatments, not only for various solid tumors but also for the treatment of other serious diseases and unmet medical needs.”

About Nuvilex

Nuvilex, Inc. (OTCQB:NVLX) is an emerging international biotechnology provider of live therapeutically valuable, encapsulated cells and services for research and medicine. Through substantial effort, aspects of our corporate activities alone and in concert with SG Austria are nearing completion, ultimately preparing us for a strong future. Nuvilex's clinical offerings will include cancer, diabetes and other treatments using the company's industry-leading cell and gene therapy expertise and cutting edge, live-cell encapsulation technology.

Safe Harbor Statement

This press release contains forward-looking statements described within the Private Securities Litigation Reform Act of 1995 involving risks and uncertainties including product demand, market competition, and meeting current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or disclose unanticipated occurrences, except as required under applicable laws.

Contact: Investor Relations Contact:
Marmel Communications, LLC
Marlin Molinaro, 702-434-8692


Posted: April 2012